BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients

Blood

Volumn 103, Issue 2, 2004, Pages 428-434

  Faulkner, Rowena D ^a   Craddock, Charles ^b   Byrne, Jennifer L ^b   Mahendra, Prem ^b   Haynes, Andrew P ^b   Prentice, Hugh G ^b   Potter, Michael ^b   Pagliuca, Antonio ^b   Ho, Aloysius ^b   Devereux, Stephen ^b   McQuaker, Grant ^b   Mufti, Ghulam ^b   Yin, John Liu ^b   Russell, Nigel H ^b  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CARMUSTINE; CYTARABINE; ETOPOSIDE; MELPHALAN;

ADULT; AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHIMERA; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MINIMAL RESIDUAL DISEASE; MORTALITY; NONHODGKIN LYMPHOMA; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; RELAPSE; REMISSION; SIBLING; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 9144239822     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-05-1406     Document Type: Article

References (26)

1. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood. 1991;77:649-653.
2. Van Beisen K, Sobocinski KA, Rowlings PA, et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood. 1998;92:1832-1836.
3. Ratanatharathorn V, Uberti J, Karanes C, et al. Prospective comparative trail of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood. 1994;84:1050-1055.
4. Tsai T, Goodman S, Saez R, et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplant. 1997;20;859-863.
5. Gajewskl JL, Phillips GL, Sobocinski KA, Armitage JO, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol. 1996;14:572-578.
6. Milpeld N, Fielding AK, Pearce RM, et al. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease: European Group for Blood and Bone Marrow Transplantation. J Clin Oncol. 1996;14:1291-1296.
7. Akpep G, Aminder RF, Piantadosi S, et al. Long-term results of blood and bone marrow transplantation for Hodgkin's Lymphoma. J Clin Oncol. 2001;19:4314-4321.
8. Kottaridis PD, Milligan D, Chopra R, et al. In vivo alemtuzumab prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000;96:2419-2425.
9. Khouri IF, Saliba RM, Giralt SA, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease and treatment-related mortality. Blood. 2001;15:3595-3599.
10. Martino R, Cabellero D, Canals C, et al. Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. Br J Haematol. 2001;115:653-659.
11. Khouri JF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using a fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;16:2817-2824.
12. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant haematological diseases. Blood. 1998;91:756-763.
13. Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant. 2000;25:345-350.
14. Hale G, Zhang M-J, Bunjes D, et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies in bone marrow transplantation. Blood. 1998;92:4581-4590.
15. Cull GM, Haynes AP, Byrne JL, et al. Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedural-related toxicity. Br J Haematol. 2000;108:754-760.
16. Cheson BD, Horning AJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:1244-1253.
17. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989;7:1630-1636.
18. Prezprioka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825-828.
19. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic haematopoietic progenitor cells with purine-analogue chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89:4531-4536.
20. Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol. 1995;13:588-595.
21. Klangsinsirikul P, Carter IG, Byrne JL, Hale G, Russell NH. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood, 2002;99:2586-2591.
22. Rebello P, Cwynarski K, Varughese M, et al. Pharmacokinetics of Campath-1H in bone marrow transplant patients. Cytotherapy. 2001;96:2419-2425.
23. Perez-Simon JA, Kottaridis PD, Martino R, et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood. 2002;100:3121-3127.
24. Marks DI, Lush R, Cavenagh J, et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning stem cell transplantation. Blood. 2002;100:3108-3114.
25. Robinson S, Goldstone A, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood. 2002;100:4310-4316.
26. Vandenbergh E, Riuz de Elvira C, Loberiza FR, et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol. 2003;120:793-800.